McKinsey to Pay $125M in Purdue Opioid Settlement

Settlement Overview

Consulting firm McKinsey & Co. has agreed to contribute $125 million to Purdue Pharma’s bankruptcy settlement. The agreement aims to resolve potential legal claims over advice the firm provided to "turbocharge" sales of the addictive painkiller OxyContin, according to court filings.

Broader Context of the Opioid Crisis

This contribution will supplement Purdue's $7.4 billion restructuring plan, which addresses accusations that the company's aggressive sales tactics fueled the U.S. opioid epidemic. While McKinsey did not admit wrongdoing in this agreement, it has previously paid $1.6 billion in settlements with government entities over its role in the crisis.

Financial Implications for Creditors

The settlement allocates an additional $50 million to the recovery fund for individuals harmed by opioids. The majority of Purdue's overall settlement funds, including a $6.5 billion contribution from the Sackler family, will go to states and local governments for addiction treatment and abatement programs.

Summary and Next Steps

This agreement marks another financial resolution for a firm involved in the opioid crisis. The settlement requires final approval from a U.S. bankruptcy judge at a hearing scheduled for April 30. Post-bankruptcy, Purdue is set to be restructured into a nonprofit named Knoa Pharma, focusing on addiction treatment medications.

FAQ

Q: Did McKinsey admit wrongdoing in this settlement?
A: No, McKinsey did not admit any wrongdoing as part of this specific $125 million settlement with Purdue.

Q: Where will the settlement money go?
A: The funds will be added to Purdue's bankruptcy estate to pay creditors, primarily states for opioid abatement, with $50 million specifically allocated to individuals harmed by the crisis.

Source: Reuters via Investing.com